Fig. 4.

HLA-DR^−/lowCD33⁺CD16⁻ cells could inhibit the development of aGVHD in humanized mouse model. a Protocol for the establishment of aGVHD model through injecting human GPBSC. Sublethally irradiated NSG mice received 5 × 10⁶ human GPBSC with or without 2.5 × 10⁶, 1 × 10⁶, and 5 × 10⁵ G-CSF-mobilized HLA-DR^−/lowCD33⁺CD16⁻ sorted from GPBSC. b Weight Loss, c median survival, and d pathological score in xenografted mice were shown. Mice co-transplanted with HLA-DR^−/lowCD33⁺CD16⁻ (pink, green, and blue, eight mice each group) had improved survival after transplant as compared with GPBSC-injected group (red). For survival, weight change, and disease score: GPBSC + high dose versus GPBSC, GPBSC + medium dose versus GPBSC, and GPBSC + low dose versus GPBSC, p < 0.05. e Representative histology of the target organs harvested on day 22 after transplantation. All results were derived from two pooled independent experiments. Each experiment was performed with G-PBSC from one donor for all recipients. Results were presented and compared with Kaplan-Meier survival curves